Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

The death of an 18-year-old aboard a Carnival Cruise Line ship earlier this month could result in charges being filed against a teenage stepbrother as the FBI continues its investigation, according to ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Journal Sentinel beat writers Mark Stewart and John Steppe break down Wisconsin athletic director Chris McIntosh's decision to retain Luke Fickell.

Who was the Milwaukee area's top prep athlete last week? You tell us. You can vote for the Piggly Wiggly Milwaukee Journal Sentinel Athlete of the Week until 3 p.m. Nov. 1. You don't have to be a ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Abstract: Numerous studies have proposed hardware architectures to accelerate sparse matrix multiplication, but these approaches often incur substantial area and power overhead, significantly ...